StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
CTSOCytosorbents Corp
stockpulse.co.kr
Nasdaq
$5.15▼ 1.84%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $323.9MShares out 62.8M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

9
  • 9.23Pre-market26.09.23 20:30
    8-KKey event#●●●#●●●

    Cytosorbents Corp

    CytoSorbents has regained compliance with the Nasdaq minimum bid price requirement of $1.00 per share, closing the matter. However, the company remains non-compliant with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million and must regain compliance by December 28, 2026.…more

    $5.15-1.84%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.16After-hours26.09.17 06:30
    4Ownership

    Cytosorbents Corp

    Insider Phillip P. Chan of Cytosorbents Corp reported a change in beneficial ownership of securities effective September 15, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock transactions.…more

    $5.15-1.84%vs prev close
    View filingShare
  • 9.16After-hours26.09.17 05:05
    4Ownership

    Cytosorbents Corp

    Insider Vincent Capponi of Cytosorbents Corp reported a change in beneficial ownership of securities effective September 14, 2026. This filing is a standard Form 4 disclosure regarding insider stock holdings.…more

    $5.15-1.84%vs prev close
    View filingShare

8 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.23Pre-market26.09.23 20:03
    #●●●

    CytoSorbents Regains Nasdaq Compliance

    CytoSorbents has regained compliance with the Nasdaq's minimum bid price requirement of $1.00 per share. The company has successfully resolved the risk of delisting by meeting the exchange's listing standards.…more

    $5.15-1.84%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.3Pre-market26.09.03 20:09

    ●●●●●●●● ●●●●● ●●●●●●

    Cytosorbents will implement a 1-for-20 reverse stock split to comply with Nasdaq's $1.00 minimum bid price requirement. The split will take effect on September 8, with trading continuing on a split-adjusted basis.…more

    $5.15-1.84%vs prev close
    ShareBenzinga
  • 9.2Pre-market26.09.02 20:30

    ●●●●●●●● ●●●●● ●●●●●●

    CytoSorbents announced that real-world analysis showed a 37% reduction in severe bleeding for urgent CABG patients using its product. The company also plans to submit its new DrugSorb-ATR for FDA approval in early 2027.…more

    $5.15-1.84%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →